Overview

A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids

Status:
Completed

Trial end date:
2017-09-25

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of Relugolix (TAK-385) 40 mg administered orally once daily for 12 weeks, compared with leuprorelin injection (once every 4 weeks, 1.88 mg or 3.75 mg subcutaneously [SC]/time) in patients with uterine fibroids.

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Leuprolide
Relugolix